Bio-Rad Laboratoriesvs.Quest Diagnostics
BIO vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Quest Diagnostics is about 2.7× larger than Bio-Rad Laboratories by market cap; Quest Diagnostics trades at the lower P/E (24.6 vs 43.5); year to date, Quest Diagnostics leads (+40.5% vs +26.0%).
Side by side
| BIO | DGX | |
|---|---|---|
| Market cap | $9.7B | $26.1B |
| Price | $390.34 | $244.51 |
| Today | +2.2% | +0.3% |
| Return YTD | +26.0% | +40.5% |
| Return 1Y | +25.7% | +35.3% |
| P/E | 43.5 | 24.6 |
| P/S | 3.7 | 2.3 |
| P/B | 1.3 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →More BIO & DGX comparisons
Other head-to-heads in the Diagnostics segment.
See where BIO and DGX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →